Dalbavancin (Dalvance)


  • Skin/Skin Structure Infections (SSI)
    • Methicillin-Sensitive Staphylococcus Aureus (MSSA) and Methicillin-Resistant Staphylcoccus Aureus (MRSA) (see Staphylococcus Aureus, [[Staphylococcus Aureus]])
    • Streptococcus Agalactiae (Group B Streptococcus) (see Streptococcus Agalactiae, [[Streptococcus Agalactiae]])
    • Streptococcus Anginosus Group (see Streptococcus Anginosus Group, [[Streptococcus Anginosus Group]])
      • Streptococcus Anginosus
      • Streptococcus Constellatus
      • Streptococcus Intermedius
    • Streptococcus Pyogenes (Group A ╬▓-Hemolytic Streptococcus) (see Streptococcus Pyogenes, [[Streptococcus Pyogenes]])


  • Glycopeptide Antibiotic


  • xxxx


  • IV: 1000 mg x1, then 500 mg one week later

Dose Adjustment

  • Hepatic: cautious use in patients with Child-Pugh class B or C patients (inadequate safety data in this group of patients)
  • Renal
    • CrCl <30 mL/min (Not on Hemodialysis): 750 mg x1, then 375 mg one week later


  • Inadequate Data

Adverse Effects

Allergic/Immunologic Adverse Effects

Gastrointestinal Manifestations

  • Clostridium Difficile Colitis (see Clostridium Difficile, [[Clostridium Difficile]])
  • Diarrhea (see Diarrhea, [[Diarrhea]]): occurs in 4.4% of cases
  • Elevated Liver Function Tests (LFT’s) (see xxxx, [[xxxx]]): elevated ALT
  • Nausea (see Nausea and Vomiting, [[Nausea and Vomiting]]): occurs in 5% of cases

Neurologic Adverse Effects

  • Headache (see Headache, [[Headache]]): occurs in 4.7% of cases

Other Adverse Effects

  • xxx
  • xxx
  • xxx


  • Dalvance┬« (dalbavancin) for injection Full Prescribing Information. Chicago, IL: Durata Therapeutics, Inc. 2014
  • Once-weekly dalbavancin versus daily conventional therapy for skin infection. N Engl J Med. 2014;370:2169-2179
  • Economic burden of hospitalization with antibiotic treatment for ABSSSI in the United States: an analysis of the Premier Hospital Database. Presented at ISPOR 2012. Washington, D.C. June 2-6, 2012. (Poster PIN22)